The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes

Drugs and Aging

Volumn 32, Issue 7, 2015, Pages 583-590

  Brunner, Martina ^a   Pieber, Thomas ^a   Korsatko, Stefan ^a   Kojzar, Harald ^a   Svendsen, Anne Louise ^b   Haahr, Hanne ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b NOVO NORDISK A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INSULIN ASPART; INSULIN ASPART PLUS INSULIN DEGLUDEC; SHORT ACTING INSULIN; ANTIDIABETIC AGENT; DRUG COMBINATION; INSULIN DEGLUDEC, INSULIN ASPART DRUG COMBINATION; LONG ACTING INSULIN;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INFUSION; GROUPS BY AGE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MAXIMUM PLASMA CONCENTRATION; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY ANALYSIS; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; STEADY STATE; AGE; BLOOD; DIABETES MELLITUS, TYPE 1; DISEASE MANAGEMENT; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; GLUCOSE CLAMP TECHNIQUE; MIDDLE AGED; POSTPRANDIAL STATE; YOUNG ADULT;

ADULT; AGE FACTORS; AGED; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DISEASE MANAGEMENT; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; GLUCOSE CLAMP TECHNIQUE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; POSTPRANDIAL PERIOD; YOUNG ADULT;

EID: 84938418281     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-015-0272-y     Document Type: Article

References (18)

1. Grant RW, Donner TW, Fradkin JE, Hayes C, Herman WH, Hsu WC, et al. Standards of medical care in diabetes 2015. Diabetes Care 2015;38(Suppl 1):S1–94.
2. Brown AF, Mangione CM, Saliba D, Sarkisian CA. Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc. 2003;51(5 Suppl Guidelines):S265–80.
3. Ligthelm RJ, Kaiser M, Vora J, Yale JF. Insulin use in elderly adults: risk of hypoglycemia and strategies for care. J Am Geriatr Soc. 2012;60(8):1564–70.
4. Jonassen I, Havelund S, Hoeg-Jensen T, Steensgaard DB, Wahlund PO, Ribel U. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29(8):2104–14.
5. Kurtzhals P, Heise T, Strauss HM, Bottcher SG, Granhall C, Haahr H, et al. Multi-hexamer formation is the underlying basis for the ultra-long glucose-lowering effect of insulin degludec. Diabetologia. 2011;54(Suppl1):S426.
6. Korsatko S, Deller S, Mader JK, Glettler K, Koehler G, Treiber G, et al. Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus. Drugs Aging. 2014;31(1):47–53.
7. Jonassen I, Hoeg-Jensen T, Havelund S, Ribel U. Ultra-long acting insulin degludec can be combined with rapid-acting insulin aspart in a soluble co-formulation. J Peptide Sci. 2010;16:32.
8. Ryzodeg EMA. EPAR. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002499/WC500139011.pdf. Accessed Mar 2015.
9. Heise T, Nosek L, Roepstorff C, Chenji S, Klein O, Haahr H. Distinct prandial and basal glucose-lowering effects of insulin degludec/insulin aspart (IDegAsp) at steady state in subjects with type 1 diabetes mellitus. Diabetes Ther. 2014;5(1):255–65.
10. Fulcher GR, Christiansen JS, Bantwal G, Polaszewska-Muszynska M, Mersebach H, Andersen TH, et al. Comparison of insulin degludec/insulin aspart and biphasic insulin aspart 30 in uncontrolled, insulin-treated type 2 diabetes: a phase 3a, randomized, treat-to-target trial. Diabetes Care. 2014;37(8):2084–90.
11. World Medical Association Declaration of Helsinki. ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191–4.
12. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Guideline for Good Clinical Practice E6(R1). June 1996. http://www.ich.org/fileadmin/Public_Web_Site/../E6_R1_Guideline.pdf. Accessed March 2015.
13. Workgroup on Hypoglycemia, American Diabetes Association. Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia. Diabetes Care. 2005;28(5):1245–9.
14. Heise T, Nosek L, Klein O, Coester H, Svendsen AL, Haahr H. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus. Diabetes Obes Metab. 2015;. doi:10.1111/dom.12463(Epub ahead of print).
15. Nosek L, Heise T, Klein O, Coester H-V, Roepstorff C, Svendsen A, Haahr H. IDegAsp produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes. Diabetologia. 2013;56(Suppl 1):S418.
16. Liu J, Wu YY, Huang XM, Yang M, Zha BB, Wang F, et al. Ageing and type 2 diabetes in an elderly Chinese population: the role of insulin resistance and beta cell dysfunction. Eur Rev Med Pharmacol Sci. 2014;18(12):1790–7.
17. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14(10):944–50.
18. Arnolds S, Kuglin B, Kapitza C, Heise T. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract. 2010;64(10):1415–24.